Two patients (1 randomized to placebo and 1 randomized to 10-mg alteplase) received 20-mg alteplase because an incorrect treatment pack had been selected. MRI indicates magnetic resonance imaging.
aAll patients randomized were considered part of the study protocol, but those without a comparative cardiac MRI were not included in the primary analysis.
bOver the course of the study, 3 patients died in the 20-mg alteplase group, 3 died in the 10-mg alteplase group, and 1 died in the placebo group.
Statistical Analysis Plan
eTable 1. Baseline Hematology and Coagulation Measured in 361 Patients
eTable 2. Procedure Characteristics and Outcomes (All Randomized Patients)
eTable 3. Prespecified Analysis of Primary Outcome for Alteplase (10-mg and 20-mg Dose Combined) vs Placebo
eTable 4. Secondary Outcomes for Efficacy and Health Outcomes for Alteplase (10-mg or 20-mg Dose) vs Placebo
eTable 5. Secondary Outcomes for Safety
eTable 6. Secondary Outcomes for Safety With Effect Estimates and 95% Confidence Intervals
eTable 7. Clinical Events
eFigure 1. Graphical Layout of the Study Protocol
eFigure 2. Clinical Case Examples
eFigure 3. Plot of Troponin T AUC
Data Sharing Statement
Customize your JAMA Network experience by selecting one or more topics from the list below.
McCartney PJ, Eteiba H, Maznyczka AM, et al. Effect of Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention on Microvascular Obstruction in Patients With Acute Myocardial Infarction: A Randomized Clinical Trial. JAMA. 2019;321(1):56–68. doi:10.1001/jama.2018.19802
In patients undergoing primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction (STEMI), does adjunctive fibrinolytic therapy with low-dose intracoronary alteplase given after reperfusion and before stent implant reduce microvascular obstruction?
In this randomized clinical trial that included 440 participants randomized to receive alteplase 20 mg, alteplase 10 mg, or placebo, the primary analysis demonstrated that the amount of microvascular obstruction (% left ventricular mass) revealed by magnetic resonance imaging was 3.5% in the alteplase 20-mg group and 2.3% in the placebo group, a difference that was not statistically significant.
Adjunctive low-dose intracoronary alteplase given early during primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction did not reduce microvascular obstruction.
Microvascular obstruction commonly affects patients with acute ST-segment elevation myocardial infarction (STEMI) and is associated with adverse outcomes.
To determine whether a therapeutic strategy involving low-dose intracoronary fibrinolytic therapy with alteplase infused early after coronary reperfusion will reduce microvascular obstruction.
Design, Setting, and Participants
Between March 17, 2016, and December 21, 2017, 440 patients presenting at 11 hospitals in the United Kingdom within 6 hours of STEMI due to a proximal–mid-vessel occlusion of a major coronary artery were randomized in a 1:1:1 dose-ranging trial design. Patient follow-up to 3 months was completed on April 12, 2018.
Participants were randomly assigned to treatment with placebo (n = 151), alteplase 10 mg (n = 144), or alteplase 20 mg (n = 145) by manual infusion over 5 to 10 minutes. The intervention was scheduled to occur early during the primary PCI procedure, after reperfusion of the infarct-related coronary artery and before stent implant.
Main Outcomes and Measures
The primary outcome was the amount of microvascular obstruction (% left ventricular mass) demonstrated by contrast-enhanced cardiac magnetic resonance imaging (MRI) conducted from days 2 through 7 after enrollment. The primary comparison was the alteplase 20-mg group vs the placebo group; if not significant, the alteplase 10-mg group vs the placebo group was considered a secondary analysis.
Recruitment stopped on December 21, 2017, because conditional power for the primary outcome based on a prespecified analysis of the first 267 randomized participants was less than 30% in both treatment groups (futility criterion). Among the 440 patients randomized (mean age, 60.5 years; 15% women), the primary end point was achieved in 396 patients (90%), 17 (3.9%) withdrew, and all others were followed up to 3 months. In the primary analysis, the mean microvascular obstruction did not differ between the 20-mg alteplase and placebo groups (3.5% vs 2.3%; estimated difference, 1.16%; 95% CI, −0.08% to 2.41%; P = .32) nor in the analysis of 10-mg alteplase vs placebo groups (2.6% vs 2.3%; estimated difference, 0.29%; 95% CI, −0.76% to 1.35%; P = .74). Major adverse cardiac events (cardiac death, nonfatal MI, unplanned hospitalization for heart failure) occurred in 15 patients (10.1%) in the placebo group, 18 (12.9%) in the 10-mg alteplase group, and 12 (8.2%) in the 20-mg alteplase group.
Conclusions and Relevance
Among patients with acute STEMI presenting within 6 hours of symptoms, adjunctive low-dose intracoronary alteplase given during the primary percutaneous intervention did not reduce microvascular obstruction. The study findings do not support this treatment.
ClinicalTrials.gov Identifier: NCT02257294
Ischemic heart disease is the leading cause of disability1 and death2 worldwide. Acute coronary thrombosis causes ST-elevation myocardial infarction (STEMI) and primary percutaneous coronary intervention (PCI) to emergently reopen the occluded coronary artery and secure vessel patency with a stent is the evidence-based standard of care.3 Primary PCI is routinely successful and normalized coronary blood flow is typically achieved in 91% of patients.4Quiz Ref ID However, failed microvascular reperfusion has been estimated to occur in 45% of all treated patients.5,6 This complication, described as microvascular obstruction, is independently predictive of an unfavorable cardiac prognosis.7 During primary PCI, distal embolization of thrombus from the lumen of the main coronary artery and microvascular thrombosis,8-12 notably of fibrin-rich microthrombi,9,12 contribute to microvascular obstruction. Clinicians lack the therapeutic tools to treat microvascular obstruction.3
Quiz Ref IDFibrinolytic therapy is also an effective treatment for acute coronary thrombosis.13 A facilitated PCI strategy involving full- or half-dose adjunctive fibrinolytic therapy given before PCI with stenting improves coronary flow acutely.14,15 However, combination-facilitated PCI involving either full-dose16 or half-dose lytic therapy17 causes paradoxical activation of thrombin, clot formation, and bleeding. Sezer et al15 modified this strategy by administering adjunctive low-dose thrombolytic therapy with 250 kU of streptokinase at the end of primary PCI. This approach appeared to improve myocardial reperfusion. Since then, fibrin-specific fibrinolytic drugs and antithrombotic pharmacotherapy for STEMI have evolved.
T-TIME investigated whether a therapeutic strategy involving low-dose intracoronary fibrinolytic therapy with alteplase infused early after coronary reperfusion would prevent and reduce microvascular obstruction.
This was a randomized, double-blind, parallel-group phase 2 clinical trial of low-dose adjunctive alteplase during primary PCI.
Screening, witnessed verbal informed consent, study drug administration, and acute assessments of efficacy took place during the standard of care primary PCI. The protocol and statistical analysis plan are provided in Supplements 1 and 2. The trial was reviewed and approved by an ethics committee of the West of Scotland Research Ethics Service (13-WS-0119), adhered to Guidelines for Good Clinical Practice in Clinical Trials,18 and complied with the Declaration of Helsinki.19
Patients with a clinical diagnosis of acute STEMI with persistent ST-segment elevation or recent left bundle-branch block with a symptom onset to reperfusion time of 6 hours or less were potentially eligible for randomization. Radial artery access was a requirement, and further angiographic criteria included a proximal–mid coronary artery occlusion (TIMI coronary flow grade 0 or 1) or, impaired coronary flow (TIMI flow grade 2, slow but complete filling) in the presence of definite angiographic evidence of thrombus (TIMI grade ≥2) in a major coronary artery. Key exclusion criteria were a functional coronary collateral supply (Rentrop grade ≥2) to the infarct-related artery, any contraindication to fibrinolysis, and lack of informed consent. The exclusion criteria are described in Supplement 3.
Race/ethnicity was designated by the patient and recorded by the local investigator to provide information on the participation of individuals with different ethnicity.
The participants were enrolled in 11 hospitals in the United Kingdom and guideline-based medical and invasive management was recommended.3 Enrollment started on March 17, 2016.
Participants were randomized by staff in the catheter laboratory using an interactive voice response–based randomization system. The randomization sequence was computer generated, using the method of randomized permuted blocks of length 6, with stratification by location of STEMI (anterior vs nonanterior) and study site (Figure). The allocation sequence was on a 1:1:1 basis between the placebo and alteplase (10 mg, 20 mg) groups and the sequence was concealed electronically. The participants, staff, and researchers were blinded to the treatment group allocation.
Primary PCI followed contemporary practice guidelines3 (Supplement 3).
Quiz Ref IDAfter successful reperfusion (TIMI flow grade ≥2), the participants received the allocated intervention immediately in the catheter laboratory. The study drug (placebo, alteplase 10 mg, or alteplase 20 mg) was manually infused before implanting the stent. The drug was reconstituted by the clinical staff using 20 mL of sterile water for injection. The cardiologist then infused the solubilized drug over 5 to 10 minutes directly into the infarct-related artery proximal to the culprit lesion using either an intracoronary catheter or the guiding catheter if selectively engaged.
The methods for the assessments of the primary and secondary outcomes are described in Supplement 3.
The primary outcome was the amount of microvascular obstruction (% of left ventricular mass) demonstrated by late gadolinium-enhanced magnetic resonance image (MRI) 10 to 15 minutes after administration of contrast media. Cardiac MRI at 1.5 T was scheduled during the index hospitalization, from days 2 through 7 after enrollment.
Magnetic resonance imaging secondary outcomes included microvascular obstruction (presence/absence), myocardial hemorrhage (presence/absence), and the amount of myocardial hemorrhage expressed as a percentage of left ventricular mass on MRI from days 2 through 7. Infarct size expressed as a percentage of left ventricular mass, myocardial salvage index, left ventricular end–diastolic volume, left ventricular end–systolic volume, and left ventricular ejection fraction were obtained on days 2 through 7 and at 3 months.
Angiographic measures of reperfusion (TIMI coronary flow grade, TIMI myocardial perfusion grade, TIMI frame count) and TIMI thrombus grade at the end of PCI were predefined secondary outcomes.
The percentage ST-segment resolution on an electrocardiogram (ECG) obtained 60 minutes after reperfusion vs before reperfusion and final infarct size revealed by the Selvester QRS score at 3 months were also calculated.
Troponin T area under the curve (AUC) was measured from blood samples obtained immediately before reperfusion (0 hours) and then again at 2 hours and at 24 hours. N-terminal pro-brain natriuretic peptide (NT-proBNP) was measured from days 2 through 7 and at 3 months after reperfusion, scheduled at the time of MRI.
Health-related quality of life (HRQoL; EuroQol 5-Dimensions 3-Level [EQ-5D-3L]) was recorded from days 2 through 7 and 3 months after the MI. The EQ-5D is a standardized instrument used as a measure of health outcome, made up of the following 2 components: first, the health utility score, a descriptive system comprising 5 dimensions—mobility, self-care, usual activities, pain or discomfort, and anxiety or depression; scores for each are combined to give a maximum value of 1. Second, the visual analog scale reports the patient’s self-rated health on a visual analog scale from 0 (worst imaginable) to 100 (best health imaginable).
Fibrinogen and other parameters of coagulation and hemostasis served as surrogate measures of bleeding risk.20,21 These parameters were measured in blood samples when site logistics permitted blood sample collection. The sampling time points were at baseline before reperfusion (0 hours) and 2, and 24 hours after reperfusion. The parameters included fibrinogen and plasminogen (both measures of coagulation and systemic fibrinolysis), fibrin D-dimer (a measure of fibrin lysis), tissue plasminogen activator (a measure of endogenous tissue plasminogen activator and any circulating alteplase), and prothrombin fragment1+2 (a measure of thrombin activation).
The adverse events and their definitions are listed in Supplement 3. A major adverse cardiovascular event (MACE) was defined as cardiovascular death, nonfatal myocardial infarction, or unplanned hospitalization for heart failure. Acute cerebrovascular and systemic bleeds were defined using the Bleeding Academic Research Consortium (BARC) criteria.22 All of these events were adjudicated by a clinical event committee who were independent of the trial and blinded to the treatment allocation. Longer-term follow-up of health outcomes (12 months, 3 years) blind to treatment group assignment is ongoing.
An independent data and safety monitoring committee and a trial steering committee coordinated the trial and communicated with the sponsor.
The target sample size was 618, based on obtaining 186 per group who had undergone an MRI within days 2 through 7 after enrollment, allowing for approximately 10% missing data. This was designed to give 90% power at a 5% significance level, to detect a difference between 2 groups of 1.72%, assuming a mean (SD) of 3.2% (5.1%) for the extent of microvascular obstruction in the comparator group. This calculation was based on the amount of microvascular obstruction demonstrated in the subgroup of patients enrolled into the MR-MI cohort study23 who fulfilled the enrollment criteria for T-TIME.
Efficacy analyses were analyzed according to randomization group, that is, in relation to randomized treatment allocation regardless of treatment received. Safety data were analyzed in relation to treatment received.
The primary outcome (extent of microvascular obstruction on MRI within days 2 through 7, as % of left ventricular mass) was compared between groups using a stratified Wilcoxon test (van Elteren test), stratified by the location of the MI. Ninety-five percent confidence intervals for between-group differences in the mean extent of microvascular obstruction were derived by bootstrap resampling (10 000 replicates), stratified by location of the MI; percentile confidence intervals are reported. The primary analysis was to compare the 20-mg alteplase group with the placebo group; if this was significant at a 5% level, then the 10-mg alteplase group would be compared with the placebo group as a primary analysis. This hierarchical approach was used to preserve the overall type I error rate at 5%. However, if the 20-mg vs placebo comparison was not significant, the 10-mg vs placebo comparison would be considered a secondary analysis. Primary and secondary outcomes were also analyzed using linear regression (continuous outcomes), logistic regression (binary outcomes), or proportional odds logistic regression (ordinal outcomes). All models were adjusted for the location of the MI. In linear regression models for continuous outcome measures, data were transformed where necessary, to improve model residual distributions, and were further adjusted for the baseline value of the outcome (where appropriate). For the primary outcome, a post hoc analysis was performed with multiple imputation for the missing outcomes. Regression models were used to assess treatment effects within prespecified subgroups through the use of treatment-by-subgroup interactions. Further details are provided in Supplement 3. All tests were 2-tailed and assessed at the 5% significance level. Missing outcome data were not imputed. Because of the potential for type I error in the analyses of secondary end points, these end points should be interpreted as exploratory. All statistical analyses were carried out with R v3.2.4 (R Development Core Team 2015) according to a prespecified statistical analysis plan.
The funder, the Efficacy and Mechanism Evaluation (EME) program of the National Institute for Health Research (NIHR), required an interim analysis for futility and specified the criteria before the start of the trial. This analysis was scheduled for when approximately 40% of patients had been randomized and followed up to 3 months. Considering the primary outcome, each active treatment group was compared with the placebo group, and if the conditional power for showing a benefit over placebo based on the current trend was less than 30%, then a recommendation would be made to halt that group.
Quiz Ref IDOn the recommendation of the data and safety monitoring committee, recruitment was discontinued on December 21, 2017, because a prespecified futility criterion for efficacy was met. Specifically, the conditional power for an analysis on the primary efficacy outcome based on 40% of the randomized population (n = 267) with follow-up to 3 months was less than 30% in both treatment groups.
By that time, 1527 patients undergoing primary PCI for acute STEMI had been screened (Figure) and 440 patients (mean age, 60.5 years; 15% women) had been randomized (151 placebo, 144 alteplase 10 mg, and 145 alteplase 20 mg) (Table 1). Seventeen patients (3.9%) withdrew from the study during follow-up. All the other participants were followed up for 3 months. The final follow-up took place on April 12, 2018.
The standard of care procedure and study intervention are illustrated in Supplement 3 and summarized in Table 2. Adjunctive study drug therapy was administered to 435 patients (98.9%); 5 patients did not receive any drug (Figure). Two patients (1 randomized to placebo and 1 randomized to 10-mg alteplase) received 20-mg alteplase because an incorrect treatment pack had been selected.
Magnetic resonance imaging was performed in 400 patients (90.9%) from days 2 through 7 after enrollment and in 367 patients (83.4%) at 3 months. The primary end point was available from 396 patients, meaning there was missing data for the primary end point in 10%. The median time to MRI was 4 days (interquartile range [IQR], 3-6 days ); for placebo, 4 days (IQR, 3-5 days); for 10-mg alteplase, 5 days (IQR, 3-6 days); and for 20-mg alteplase, 4 days (IQR, 3-6 days). The median from reperfusion to the 3-month MRI were 91 days (IQR, 86-97 days). Microvascular obstruction was demonstrated in 176 patients (44.4%), and the amount of microvascular obstruction, expressed as the mean percentage of left ventricular mass, was 2.80%. Two clinical case examples are illustrated in eFigure 2 in Supplement 3.
In the primary analysis, the amount of microvascular obstruction revealed by MRI did not differ between the 20-mg alteplase group and the placebo group (mean, 3.5% vs 2.3%; estimated difference, 1.16%; 95% CI, −0.08% to 2.41%; van Elteren test, P = .32). The comparison of the 10-mg alteplase group and the placebo group then became secondary (mean, 2.6% vs 2.3%; estimated difference, 0.29%; 95% CI, −0.76% to 1.35%; van Elteren test, P = .74; Table 3). Similar results were obtained using a linear regression model; with no evidence of a difference in the primary outcome between all patients randomized to alteplase and those randomized to placebo, mean difference on square root scale, 0.15 (95% CI, −0.12 to 0.42; P = .28).
A post hoc analysis of the primary outcome including multiple imputation for the missing values was performed, which produced similar results to the primary analysis.
Treatment effect differences on the primary outcome between prespecified subgroups defined by baseline characteristics were assessed. None of the interaction tests were statistically significant (Table 3 and Table 4 and eTable 3 in Supplement 3). In the subgroup of patients presenting at more than 4 hours, the estimated mean difference in the square root of the amount of microvascular obstruction between the 20-mg alteplase group (n = 27) and the placebo group (n = 26) was 1.12 (95% CI, 0.42-1.82; P = .002); however, the test for interaction was not statistically significant (P = .06), so this subgroup finding should not be interpreted as different from the overall effect.
The AUC for troponin T measured at baseline and at 2 and 24 hours after reperfusion among 317 patients was increased in both treatment groups compared with placebo (eTable 4 in Supplement 3; relative difference, 1.53; 95% CI, 1.16-2.01; P = .002) for both alteplase groups combined vs placebo). The troponin T AUC was 35% higher in patients treated with 20 mg of alteplase vs placebo (relative ratio, 1.53; 95% CI, 1.12-2.11; P = .008).
Health-related quality of life scores were not significantly different between the groups at 3 months. The EQ-5D health utility scores were 0.88 in both the 20-mg alteplase and placebo groups (mean difference, −0.002; 95% CI, −0.04 to 0.04; P = .93; Table 5).
Compared with placebo, there was a dose-related increase in the systemic concentrations of fibrin D-dimer and prothrombin F1 + 2, and a slight reduction in plasminogen, in the alteplase groups (eTable 5 in Supplement 3). The systemic concentrations of fibrinogen and hemoglobin were numerically similar between the groups.
The adverse events are described in eTable 7 in Supplement 3. MACE occurred in 15 patients (10.1%) in the placebo group, 18 (12.9%) in the 10-mg alteplase group, and 12 (8.2%) in the 20-mg alteplase group. Two patients experienced a stroke. Aspiration thrombectomy was used in 1 of these patients who developed a homonynous hemianopia after the procedure. Major bleeds were uncommon, occurring in 1 patient in each of the 10-mg and 20-mg alteplase groups.
Quiz Ref IDAmong patients with acute STEMI presenting within 6 hours of symptom onset, adjunctive low-dose intracoronary alteplase given during the primary PCI compared with placebo did not reduce microvascular obstruction.
This trial has several strengths. Comparable in scale with other pivotal trials involving cardiac MRI,24 including the INFUSE-AMI 4 and AIDA STEMI24,25 trials, the trial design selected patients with presenting characteristics that increase infarct size, eg, proximal occlusion of a thrombus-laden coronary artery. Mean infarct size (27% of left ventricular mass) was almost 2-fold larger than that observed in an unselected population of patients with STEMI.5,6 By limiting eligibility to an ischemic time of 6 or fewer hours, the aim was to include participants with salvageable myocardium. Alteplase was used within its licensed indication and at doses that are available in the clinic. Bias was minimized through a double-blind design and use of core laboratory analyses. The increase in systemic concentrations of fibrin D-dimers without any change in fibrinogen indicates that fibrinolysis or fibrin generation were localized to the heart.
The potential for harm with facilitated PCI was highlighted in the ASSENT-4 (Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention 4)16 and FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events)17 trials. In ASSENT-4,16 compared with primary PCI (standard care), full-dose tenecteplase combined with PCI was associated with an increase in the primary end point of death, congestive heart failure, or shock within 90 days. Ischemic cardiac complications and ischemic stroke were also increased in the intervention group. Despite more initial patency in the infarct-related artery, residual thrombus burden was higher in the facilitated PCI group and tissue reperfusion and clinical outcomes were worse.26 These results may be explained by comparatively inadequate anticoagulation and, potentially, formation of fibrin and thrombus in the group treated with tenecteplase.26,27 The importance of effective anticoagulation to mitigate the prothrombotic effects of fibrinolytic therapy with alteplase has been reported previously.27
The targeted, intracoronary infusion of the study drug was intended to minimize the systemic release of alteplase and minimize bleeding events. Alteplase was selected because it is a fibrin-specific fibrinolytic drug with a brief circulating half-life ( ≈ 5 minutes). In order to further reduce the possibility of harmful remote bleeds, patients with risk factors for bleeding were excluded and the PCI procedures were performed via the radial artery. The rates of bleeding events were within the expected range for primary PCI.28
The increase in troponin T in the alteplase groups may provide mechanistic insights. The troponin T AUC is distinct from the other measures of infarct size that were obtained at single time points. An alternative explanation such as biomarker washout after fibrinolysis may explain why this rise in troponin was not associated with an increase in MRI measures of infarction. The dose-related increase in the systemic concentrations of fibrin D-dimer indicates that clot lysis had occurred. An increase in prothrombin F1 + 2 concentrations was observed in the alteplase groups, despite achieving therapeutic anticoagulation with unfractionated heparin. The undesired procoagulant effect of fibrinolytic therapy through thrombin activation27 may have led to microvascular thrombosis, limiting the efficacy of the intervention.
Contemporary practice guidelines call for more research to identify new treatments for microvascular obstruction.3 There is growing interest in the potential efficacy of adjunctive intracoronary fibrinolytic therapy during primary PCI. Two phase 3 trials are investigating the efficacy of reduced doses of either alteplase (STRIVE, NCT03335839) or tenecteplase (RESTORE-MI; ACTRN12618000778280) (Supplement 3).
The study had several limitations. First, the study presents short-term findings up to 3 months. Second, the trial was discontinued when prespecified futility criteria were met. The interim analysis and related stopping criteria had been required and specified by the funder. The objectives of this phase 2 trial included evidence synthesis for mechanisms evaluation as well as efficacy. To an extent, premature discontinuation limits the mechanisms evaluation. Third, because of the large number of secondary end points and the potential for type I error, all of these findings should be interpreted as only exploratory. Fourth, study drug administration was focused at a single time point before stent implant when coronary blood flow was variable. Alternatively, in the STRIVE and RESTORE-MI trials, the intervention is scheduled at the end of primary PCI, after stent implant.
Among patients with acute STEMI presenting within 6 hours of symptoms, adjunctive low-dose intracoronary alteplase given during the primary percutaneous intervention compared with placebo did not reduce microvascular obstruction. The study findings do not support this treatment.
Corresponding Author: Colin Berry, PhD, British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, 126 University Pl, University of Glasgow, Glasgow, G12 8TA, Scotland, United Kingdom (firstname.lastname@example.org).
Accepted for Publication: November 20, 2018.
Author Contributions: Dr Berry had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Eteiba, Greenwood, Chowdhary, Lindsay, Sattar, I. Ford, Berry.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: McCartney, Muir, Gershlick, Berry.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: McConnachie.
Obtained funding: Greenwood, Sattar, I. Ford, Berry.
Administrative, technical, or material support: McCartney, Eteiba, Maznyczka, McEntegart, Greenwood, Chowdhary, Gershlick, Cotton, Wragg, Curzen, Rocchiccioli, Good, Martin, Gillespie, T. Ford, Petrie, Macfarlane, Tait, Welsh, Weir, Berry.
Supervision: Eteiba, McEntegart, Muir, Oldroyd, Lindsay, Good, Watkins, Petrie, Fox, I. Ford, Berry.
Conflict of Interest Disclosures: Dr Maznyczka reported participating in the British Heart Foundation Clinical Research Training Fellowship (FS/16/74/32573) during the conduct of the study. Dr Curzen reported receiving unrestricted research grants and fees for lectures and consultancy from Abbott Vascular and Boston Scientific, personal fees from HeartFlow and Haemonetics, and grants from Beckman Coulter, outside the submitted work. Dr Tait reported receiving grants from National Institute for Health Research (NIHR) during the conduct of the study; consultancy fees and honoraria from Boehringer-Ingelheim, personal fees and nonfinancial support from Bayer Healthcare, personal fees from Pfizer and Shire, and nonfinancial support from NovoNordisk. Dr Welsh reported receiving grants from the Chief Scientist Office, Boehringer-Ingelheim, and Roche. Dr Sattar reported receiving grants and personal fees from Boehringer-Ingelheim, personal fees from Amgen, Eli Lilly, Janssen, and AstraZeneca outside the submitted work. Dr Fox reported receiving grants and personal fees from Bayer/Janssen, Sanofi/Regeneron, and Verseon and grants from AstraZeneca. Drs I. Ford and McConnachie reported receiving grants from the NIHR Efficacy and Mechanism Evaluation (EME) Programme during the conduct of the study. Dr Berry reported receiving research grants from the NIHR EME Programme and British Heart Foundation; receiving nonfinancial support from Boehringer-Ingelheim during the conduct of the study; receiving research support to his institution from Abbott Vascular, AstraZeneca, Boehringer-Ingelheim, HeartFlow, GlaxoSmithKline, Novartis, Philips, and Siemens Healthcare; serving as chair of the clinical trials committee of the Society for Cardiovascular Magnetic Resonance and treasurer of the British Society of Cardiovascular Magnetic Resonance. Dr McCartney reported receiving grants from National Institute for Health Research (NIHR) during the conduct of the study. No other disclosures were reported.
Funding/Support: This work was supported by grant 12/170/45 from the NIHR EME, and Boehringer-Ingelheim provided the study drugs. Dr Maznyczka was funded by a fellowship from the British Heart Foundation (FS/16/74/32573). Drs Berry, Petrie, and Sattar are supported by grant RE/18/6/34217 from the British Heart Foundation. The research was in part supported by the NIHR infrastructure at Leeds.
Role of the Funder/Sponsor: The funder, NIHR-EME, coordinated peer review, approved the design of the study and had oversight of its conduct and management. The University of Glasgow and Greater Glasgow and Clyde Health Board were independent cosponsors of the trial. The cosponsors shared oversight and responsibility for the design and conduct of the study; collection, management, research governance, analysis, and final approval of the manuscript; the sponsor did not have the right to preclude submission of the manuscript.
T-TIME Group Collaborators
Responsible Individual at Data Coordinating Centre: Alex McConnachie.
Data Coordinating Centre(s): Robertson Centre for Biostatistics, Glasgow Clinical Trials Unit, University of Glasgow.
Participating Sites:West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital, Clydebank, UK: David Corcoran, MRCP; Andrew Davie, FRCP; Stuart Hood, FRCP; Joanne Kelly, RN; Tom Krysztofiak, MRCP; Victoria McNulty, MPharm (Hons); Vanessa Orchard, HCPC; and Jackie Wales, FIBMS; Liverpool Heart and Chest Hospital NHS Foundation Trust: Suneil Aggarwal, FRCP; Turab Ali, FRCP; Fiona Andrews, BN; Nicola Browning, PhD; Timothy A. Fairbairn, FRCP; Ruth Hardwick, MPharm; J Hasleton, FRCP; Babu Kunadian, FRCP; Pradeep Magapu, FRCP; Nick Palmer, FRCP; Rodney Stables, FRCP; Clive Taylerson; Hoi Tong, HCPC; Sophie Twiss, BN; and Periaswamy Velavan, FRCP; University Hospital Southampton Foundation Trust: Karen Banks, RN; Simon Corbett, FRCP; Michael Mahmoudi, FRCP; Zoe Nicholas, BSc; and James Wilkinson, FRCP; Leeds University Hospitals NHS Trust: Matthew Allan, MRCP; Michelle Anderson, RN; Daniel J Blackman, MD, MRCP; Jonathan Blaxill, FRCP; Michael Cunnington, MD; Vivek Kodoth, FRCP; John Kurian, FRCP; Steven Lindsay, FRCP; Christopher Malkin, FRCP; Jim McLenachan, FRCP; Kathryn Somers, RN; and Murgugapathy Veerasamy, FRCP; Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust: Reenamol Abraham, RN; David Adlam, FRCP; Stephen Coleman, BPharm; Ian Hudson, FRCP; Andrew Ladwiniec, MRCP; Gerald P. McCann, MD; Emma Parker, RN; Elved Roberts, MD; and Joanne Wormleighton, DCR(R); Wythenshawe Hospital, Manchester University NHS Foundation Trust: Eltigani Abdelaal, MRCP; Hussain Contractor, FRCP; Beatriz Duran, BS Pharm; Robin Egdell, FRCP; Susan Ferguson, BN; Sarra Giannopoulou, BN; Sanjay Sastry, FRCP; Jaydeep Sarma, FRCP; Matthias Schmitt, FRCP; and Sophie Quinn, BN; Barts Health NHS Trust, London: Andrew Archbold, FRCP; Mervyn Andiapen, DN; Charity Evwierhoma, BN; Ajay Jain, FRCP; Dan Jones, FRCP; Simon Kennon, FRCP; James Moon, FRCP; Anthony Mathur, FRCP; Amy Richards, BSc; and Alexander Sirker, FRCP; The James Cook University Hospital, South Tees Hospitals NHS Foundation Trust, Middlesbrough: David Austin, FRCP; Mark de Belder, FRCP; Justin Carter, MRCP; Nicola Cunningham, BSc (Hons); Rachel Dale, HCPC; Jim Hall, FRCP; Stephanie Mack, BSc (Hons); Tracy Manders, RN; Neil Maredia, MD; Karen McLeod, BSc (Hons); Luca Settimo, PhDPharm; Andrew Sutton, FRCP; Neil Swanson, FRCP; Paul Williams, FRCP; and Robert Wright, FRCP; New Cross Hospital, Wolverhampton University Hospital NHS Trust: Victoria Cottam, BN; Elizabeth Radford; and Ben Wrigley, FRCP; Freeman Hospital, The Newcastle Upon Tyne Hospital NHS Foundation Trust: Rajiv Das, FRCP; Samantha Jones, BN; and Vera Wealleans, BN; Royal Infirmary of Edinburgh, NHS Lothian: Nick Cruden, FRCP; Laura Flint, BN; and Ruaridh Buchan, MPharm; University Hospitals Bristol NHS Foundation Trust: Chiara Bucciarelli-Ducci, FRCP; Tom Johnson, FRCP; Vincy Johny, BN; and Liz McCullagh, BPharm.
Clinical Event Committee: Robin A. Weir, MRCP; University Hospital Hairmyres Hospital, NHS Lanarkshire, UK; Aengus Murphy, MD; University Hospital Monklands, NHS Lanarkshire, UK; Colin J. Petrie, PhD; University Hospital Monklands, NHS Lanarkshire, UK; and Eleanor Dinnett, MBChB; Robertson Centre for Biostatistics, University of Glasgow.
Independent Data and Safety Monitoring Committee: Gary A. Ford, MB, BChir, University of Oxford, UK; Chim C. Lang, FRCP, University of Dundee, UK; and John Norrie, MSc; University of Edinburgh, UK.
Trial Steering Committee: Keith A. Fox, FRCP, University of Edinburgh; Colin Berry, FRCP, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow; Rajesh Kharbanda, FRCP, Oxford University Hospitals NHS Foundation Trust; Catherine Labinjoh, FRCP, Forth Valley Royal Hospital, NHS Forth Valley; Gordon Baird, MRCGP, Stranraer; Sandra Pairman, BN, Golden Jubilee National Hospital; David Jamieson, PhD, Robertson Centre for Biostatistics, University of Glasgow; Sarah Weeden, PhD, Robertson Centre for Biostatistics, University of Glasgow; Jurgen Van-Melckebeke, BSc, Project Management Unit, Glasgow Clinical Research Facility, Greater Glasgow and Clyde Health Board; Elizabeth Douglas, PhD, Clinical Trials Pharmacy, Clinical Research and Development, Greater Glasgow and Clyde Health Board; Pamela Surtees, Clinical Trials Pharmacy, Clinical Research and Development, Greater Glasgow and Clyde Health Board; Barbara Ross, BSc (Hons), Clinical Research and Development, Greater Glasgow and Clyde Health Board; Gemma Brindley, PhD, Clinical Research and Development, Greater Glasgow and Clyde Health Board; Sheila McGowan, PhD, Clinical Research and Development, Greater Glasgow and Clyde Health Board; Emma Jane Gault, MA (Hons), College of Medical, Veterinary and Life Sciences, University of Glasgow; Debra Stuart, PhD, College of Medical, Veterinary and Life Sciences, University of Glasgow; Maureen Travers, PhD, R&D Office, Clinical Research and Development, Greater Glasgow and Clyde Health Board; Marc Jones, PhD, Pharmacovigilance Office, Clinical Research and Development, Greater Glasgow and Clyde Health Board; Sharon Kean, Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow; Caroline Watson, PhD, R&D Governance, Clinical Research and Development, Greater Glasgow and Clyde Health Board; Emma Miller, Project Management Unit, Glasgow Clinical Research Facility, Greater Glasgow and Clyde Health Board; Eamonn Bolger, BSc, College of Medical, Veterinary and Life Sciences, University of Glasgow; Gillian Thomson, Project Management Unit, Glasgow Clinical Research Facility, Greater Glasgow and Clyde Health Board; Elaine Butler, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow; Josephine Cooney, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow; Julie Kennedy, MSc, Electrocardiology Core Laboratory, University of Glasgow; Emma Leishman, BSc, Department of Haematology, Royal Infirmary, Glasgow; Jaclyn Carberry, MBChB (Hons), Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow; David Corcoran, MRCP, West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital, Clydebank; and Aleksandra Radjenovic, PhD, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow.
Data Sharing Statement: See Supplement 4.
Additional Contributions: We thank all of the other clinical staff and the patients who participated in this project.
Create a personal account or sign in to: